Callan JMB, Inc. CJMB 深 滬
等待開盤 05-20 09:30:00 美东时间
0.7918
-0.188
-19.20%
華盛通- 最 高0.82
- 今 開0.7616
- 成交量 735.10万股
- 最 低 0.68
- 昨 收 0.98
- 總市值 445.57万
- 52周最高 5.88
- 市盈率 靜 --
- 換手率 130.63%
- 52周最低 0.68
- 委 比 -90.77%
- 總股本 562.74万
- 歷史最高 7.7599
- 量 比 161.89
- 振 幅 14.29%
- 歷史最低 0.68
- 每 手 1
- 風險率 1.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Callan Jmb Q1 EPS $(0.59) Down From $(0.32) YoY, Sales $1.106M Down From $1.449M YoY
Callan Jmb (NASDAQ:CJMB) reported quarterly losses of $(0.59) per share. This is a 84.37 percent decrease over losses of $(0.32) per share from the same period last year. The company reported $1.106 million in sales
05-16 06:14
12 Industrials Stocks Moving In Thursday's Pre-Market Session
Gainers Concorde Intl Gr (NASDAQ:YOOV) shares moved upwards by 94.9% to $1.35 ...
05-14 20:05
12 Industrials Stocks Moving In Wednesday's Pre-Market Session
Gainers Bloom Energy (NYSE:BE) stock increased by 18.8% to $269.0 during Wedne...
04-29 20:05
Callan Jmb Q4 EPS $(0.56), Sales $1.161M
Callan Jmb (NASDAQ:CJMB) reported quarterly losses of $(0.56) per share. The company reported $1.161 million in sales this quarter.
04-01 05:28
12 Industrials Stocks Moving In Friday's Intraday Session
Gainers Globavend Holdings (NASDAQ:GVH) shares increased by 36.0% to $1.4 duri...
03-28 01:05
Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight
Callan JMB joins DifGen, Aveva, Attune Biotech, SGP in JKB-122 immune platform scale-up collaboration; provides independent manufacturing and supply chain oversight Callan JMB will act as an independent infrastructure and oversight partner in a collaboration led by DifGen Pharmaceuticals and Aveva D
03-27 20:45
Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement
<p>Callan JMB Inc. announced its role as an independent oversight partner in a collaboration led by DifGen Pharmaceuticals, Aveva Drug Delivery Systems, and Biostax Corp (doing business as Attune Biotech) to support U.S.-based manufacturing and supply chain operations for the JKB-122 (Lodonal™) immune restoration platform. The collaboration focuses on ensuring compliance with federal standards, particularly for Phase 2b/3 clinical development and...
03-27 12:45
Callan JMB Agrees With Attune Biotech To Support Its IND Clinical Trials For Treatment Of Post-Acute Sequelae Of SARS-CoV-2 Infection
Callan JMB will Provide Independent Manufacturing Oversight and Governance as lodonal™ Undergoes Clinical Trials for Underserved Patient Population SPRING BRANCH, Texas, March 11, 2026 (GLOBE NEWSWIRE) --
03-11 20:49
Callan JMB Inc. partners with Attune Biotech to oversee lodonal IND manufacturing and quality control
Callan JMB Inc. partners with Attune Biotech to oversee lodonal IND manufacturing and quality control Callan JMB agreed with Attune Biotech to oversee manufacturing and quality control for Attune’s investigational new drug clinical trials of lodonal for Long COVID. Under the agreement, Callan JMB wi
03-11 20:45
